ALTK & DSAEK offer fast visual recovery

Article

Automated lamellar therapeutic keratoplasty (ALTK) and Descemet stripping automated endothelial keratoplasty (DSAEK) are both safe and effective techniques for corneal transplantation.

Automated lamellar therapeutic keratoplasty (ALTK) and Descemet stripping automated endothelial keratoplasty (DSAEK) are both safe and effective techniques for corneal transplantation, according to Paolo Garimoldi and colleagues from Ospedale di Circolo, Italy.

Twenty eyes, 18 affected by keratocone and 2 by stromal opacity for herpes simplex keratitis, underwent ALTK. In eyes with keratocone, releasing penetrating stromal incisions were performed and a thicker graft obtained from a donor cornea, which was transplanted. The 18 eyes affected by Fuchs endothelial dystrophy underwent DSAEK; after removing the endothelium and Descemet membrane, a graft of deep stroma and endothelium from the donor cornea was inserted in the anterior chamber and positioned with an air-bubble.

Eyes treated with ALTK demonstrated very good graft transparency and an excellent quality of interface. No rejection reactions were noted and early temporary de-epithelialization occurred in 20% of cases. Best corrected visual acuity (BCVA) was 0.6 or better in 90% of subjects after three months follow-up. The eyes treated with DSAEK demonstrated a progressive increase of corneal transparency and the BCVA was 0.5 or better in 70% of cases after three months follow-up.

It was concluded that both procedures are safe and effective, particularly with regards the fast visual recovery and low level of complications.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
© 2025 MJH Life Sciences

All rights reserved.